These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24444516)

  • 41. SGLT2 inhibitors: new reports.
    Med Lett Drugs Ther; 2015 Oct; 57(1479):139-40. PubMed ID: 26445203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
    Rizos EC; Elisaf MS
    Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Positive experience with SGLT-2 inhibitor in general practice].
    Fath R
    MMW Fortschr Med; 2015 Jul; 157(13):83. PubMed ID: 26206058
    [No Abstract]   [Full Text] [Related]  

  • 44. Canagliflozin: a new hope in the antidiabetic armamentarium.
    Katsi VK; Michalakeas CA; Grassos CE; Vamvakou GD; Lekakis JP; Tousoulis D; Stefanadis CI; Makris TK; Kallikazaros IE
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):216-20. PubMed ID: 24359233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.
    Suissa S
    Circulation; 2018 Apr; 137(14):1432-1434. PubMed ID: 29610125
    [No Abstract]   [Full Text] [Related]  

  • 47. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
    Cuypers J; Mathieu C; Benhalima K
    Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
    Riser Taylor S; Harris KB
    Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New diabetes drugs go beyond insulin to flush out excess sugar.
    Heger M
    Nat Med; 2011 Jun; 17(6):636. PubMed ID: 21647124
    [No Abstract]   [Full Text] [Related]  

  • 50. The EMPA-REG study: What has it told us? A diabetologist's perspective.
    DeFronzo RA
    J Diabetes Complications; 2016; 30(1):1-2. PubMed ID: 26541076
    [No Abstract]   [Full Text] [Related]  

  • 51. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
    Scheen AJ
    Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
    Mende CW
    Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
    Cherney DZ; Udell JA
    Circulation; 2016 Dec; 134(24):1915-1917. PubMed ID: 27956401
    [No Abstract]   [Full Text] [Related]  

  • 54. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Canagliflozin: first global approval.
    Elkinson S; Scott LJ
    Drugs; 2013 Jun; 73(9):979-88. PubMed ID: 23729000
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2.
    Ghezzi C; Loo DDF; Wright EM
    Diabetologia; 2018 Oct; 61(10):2087-2097. PubMed ID: 30132032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.
    Weir MR
    Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
    de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
    Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
    Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.